125 related articles for article (PubMed ID: 32275644)
1. Inhibitor of Differentiation 1 (ID1) Facilitates the Efficacy of Sorafenib in Non-Small Cell Lung Cancer Cells through Suppressing Epithelial to Mesenchymal Transition.
Zhao YX; Liu J
Med Sci Monit; 2020 Apr; 26():e922148. PubMed ID: 32275644
[TBL] [Abstract][Full Text] [Related]
2. ID1 overexpression increases gefitinib sensitivity in non-small cell lung cancer by activating RIP3/MLKL-dependent necroptosis.
Tan HY; Wang N; Chan YT; Zhang C; Guo W; Chen F; Zhong Z; Li S; Feng Y
Cancer Lett; 2020 Apr; 475():109-118. PubMed ID: 32004572
[TBL] [Abstract][Full Text] [Related]
3. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
[TBL] [Abstract][Full Text] [Related]
4. The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche.
Castañón E; Soltermann A; López I; Román M; Ecay M; Collantes M; Redrado M; Baraibar I; López-Picazo JM; Rolfo C; Vidal-Vanaclocha F; Raez L; Weder W; Calvo A; Gil-Bazo I
Cancer Lett; 2017 Aug; 402():43-51. PubMed ID: 28549790
[TBL] [Abstract][Full Text] [Related]
5. Nicotine-mediated invasion and migration of non-small cell lung carcinoma cells by modulating STMN3 and GSPT1 genes in an ID1-dependent manner.
Nair S; Bora-Singhal N; Perumal D; Chellappan S
Mol Cancer; 2014 Jul; 13():173. PubMed ID: 25028095
[TBL] [Abstract][Full Text] [Related]
6. Scutellaria Flavonoids Effectively Inhibit the Malignant Phenotypes of Non-small Cell Lung Cancer in an Id1-dependent Manner.
Zhao Z; Liu B; Sun J; Lu L; Liu L; Qiu J; Li Q; Yan C; Jiang S; Mohammadtursun N; Ma W; Li M; Dong J; Gong W
Int J Biol Sci; 2019; 15(7):1500-1513. PubMed ID: 31337979
[TBL] [Abstract][Full Text] [Related]
7. ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signaling.
Pillai S; Rizwani W; Li X; Rawal B; Nair S; Schell MJ; Bepler G; Haura E; Coppola D; Chellappan S
Mol Cell Biol; 2011 Jul; 31(14):3052-67. PubMed ID: 21606196
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of M2 AChR/NF-κB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC).
Zhao Q; Yue J; Zhang C; Gu X; Chen H; Xu L
Oncotarget; 2015 Oct; 6(30):29335-46. PubMed ID: 26336823
[TBL] [Abstract][Full Text] [Related]
9. Activation of histamine H4 receptors decreases epithelial-to-mesenchymal transition progress by inhibiting transforming growth factor-β1 signalling pathway in non-small cell lung cancer.
Cai WK; Hu J; Li T; Meng JR; Ma X; Yin SJ; Zhao CH; He GH; Xu GL
Eur J Cancer; 2014 Apr; 50(6):1195-206. PubMed ID: 24447834
[TBL] [Abstract][Full Text] [Related]
10. GCIP functions as a tumor suppressor in non-small cell lung cancer by suppressing Id1-mediated tumor promotion.
Chen KY; Chen CC; Tseng YL; Chang YC; Chang MC
Oncotarget; 2014 Jul; 5(13):5017-28. PubMed ID: 24970809
[TBL] [Abstract][Full Text] [Related]
11. [Relationship between ID1 and EGFR-TKI Resistance
in Non-small Cell Lung Cancer].
Bao Y; Zhao Y; Chen B; Luo J; Deng Q; Sun H; Xie B; Zhou S
Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):864-870. PubMed ID: 27978873
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of ZNF746 suppresses invasion and epithelial to mesenchymal transition in H460 non-small cell lung cancer cells.
Kim B; Sohn EJ; Jung JH; Shin EA; You OH; Im J; Kim SH
Oncol Rep; 2014 Jan; 31(1):73-8. PubMed ID: 24145959
[TBL] [Abstract][Full Text] [Related]
13. ZEB1-AS1 is associated with poor prognosis in non-small-cell lung cancer and influences cell migration and apoptosis by repressing ID1.
Jin J; Wang H; Si J; Ni R; Liu Y; Wang J
Clin Sci (Lond); 2019 Jan; 133(2):381-392. PubMed ID: 30626729
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of N-Acetylglucosaminyltransferase GCNT3 by miR-302b-3p Decreases Non-Small Cell Lung Cancer (NSCLC) Cell Proliferation, Migration and Invasion.
Li Q; Ran P; Zhang X; Guo X; Yuan Y; Dong T; Zhu B; Zheng S; Xiao C
Cell Physiol Biochem; 2018; 50(3):987-1004. PubMed ID: 30355927
[TBL] [Abstract][Full Text] [Related]
16. Repression of TIF1γ by SOX2 promotes TGF-β-induced epithelial-mesenchymal transition in non-small-cell lung cancer.
Wang L; Yang H; Lei Z; Zhao J; Chen Y; Chen P; Li C; Zeng Y; Liu Z; Liu X; Zhang HT
Oncogene; 2016 Feb; 35(7):867-77. PubMed ID: 25961934
[TBL] [Abstract][Full Text] [Related]
17. Deguelin inhibits epithelial-to-mesenchymal transition and metastasis of human non-small cell lung cancer cells by regulating NIMA-related kinase 2.
Zhao D; Han W; Liu X; Cui D; Chen Y
Thorac Cancer; 2017 Jul; 8(4):320-327. PubMed ID: 28509438
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2.
Ye Z; Yin S; Su Z; Bai M; Zhang H; Hei Z; Cai S
Oncotarget; 2016 Jun; 7(25):37524-37535. PubMed ID: 27229528
[TBL] [Abstract][Full Text] [Related]
19. Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance.
Ponz-Sarvisé M; Nguewa PA; Pajares MJ; Agorreta J; Lozano MD; Redrado M; Pio R; Behrens C; Wistuba II; García-Franco CE; García-Foncillas J; Montuenga LM; Calvo A; Gil-Bazo I
Clin Cancer Res; 2011 Jun; 17(12):4155-66. PubMed ID: 21540238
[TBL] [Abstract][Full Text] [Related]
20. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
He Y; Xie H; Yu P; Jiang S; Wei L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
